Quercetin inhibits angiogenesis‑mediated human retinoblastoma growth by targeting vascular endothelial growth factor receptor

Song,Wei; Zhao,Xiaofei; Xu,Jiarui; Zhang,Han

doi:10.3892/ol.2017.6623

Quercetin inhibits angiogenesis‑mediated human retinoblastoma growth by targeting vascular endothelial growth factor receptor

Authors:
- Wei Song
- Xiaofei Zhao
- Jiarui Xu
- Han Zhang
View Affiliations

Affiliations: Department of Ophthalmology, The Second Hospital of Shandong University, Jinan, Shandong 250000, P.R. China, Department of Emergency, Shandong Provincial Hospital, Jinan, Shandong 250000, P.R. China
Published online on: July 20, 2017 https://doi.org/10.3892/ol.2017.6623
Pages: 3343-3348
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoblastoma (RB) is the most common malignant intraocular cancer in teenagers, occurrence of which depends on the mutation of multiple genes. Among all the signaling pathways involved in the oncogenesis of RB, the process of angiogenesis has been demonstrated to be associated with the local invasive growth and metastasis of this cancer type. Quercetin (Que) is a typical flavonoid and has been reported to inhibit angiogenesis in various types of tumors. In the present study, the effect of Que on RB cells and angiogenesis of RB was evaluated. The human RB Y79 cell line was subjected to treatment with Que of various concentrations. Viability, invasion and migration ability and apoptosis of Y79 cells were subsequently measured to assess the effect of Que on RB cells. In addition, the expression of vascular endothelial growth factor receptor (VEGFR) was also quantified. It was revealed that Que inhibited RB cell growth and invasion in vitro in a dose‑dependent manner, with 100 µM Que exhibiting the strongest inhibitory effect. In addition, Que downregulated the expression of VEGFR, which was an indicator of the blockade of angiogenesis in RB by targeting VEGF. The effect of Que on angiogenesis was also observed to be dose‑dependent. The results of the present study indicated that Que may be a potential anti‑RB therapy due to its anti‑angiogenesis effect.

View Figures

View References

1	Menon BS, Alagaratnam J, Juraid EA, Mohamed M, Ibrahim H and Naing NN: Late presentation of retinoblastoma in Malaysia. Pediatr Blood Cancer. 52:215–217. 2009. View Article : Google Scholar : PubMed/NCBI
2	Bowman RJ, Mafwir MI, Luther P, Luande J and Wood M: Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer. 50:160–162. 2008. View Article : Google Scholar : PubMed/NCBI
3	Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ and Boyd NW: Presenting signs of retinoblastoma. J Pediatr. 132:505–508. 1998. View Article : Google Scholar : PubMed/NCBI
4	Kivelä T: The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Brit J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar
5	Leal-Leal C, Flores-Rojo M, Medina-Sansón A, Cerecedo-Díaz F, Sánchez-Félix S, González-Ramella O, Pérez-Pérez F, Gómez-Martínez R, Quero-Hernández A, Altamirano-Alvarez E, et al: A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol. 88:1074–1077. 2004. View Article : Google Scholar : PubMed/NCBI
6	Comings DE: A general theory of carcinogenesis. Proc Natl Acad Sci USA. 70:3324–3328. 1973. View Article : Google Scholar : PubMed/NCBI
7	Friend SH, Bernards RA, Rogelj S, Weinberg RA, Rapaport JM, Albert DM and Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:643–646. 1986. View Article : Google Scholar
8	Alfred G and Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA. 68:820–823. 1971. View Article : Google Scholar : PubMed/NCBI
9	Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS and Gallie BL: Retinoblastoma. Lancet. 379:1436–1446. 2012. View Article : Google Scholar : PubMed/NCBI
10	Shields CL and Shields JA: Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol. 17:228–234. 2006. View Article : Google Scholar : PubMed/NCBI
11	Saxena P and Kaur J: Differential expression of genes in retinoblastoma. Clin Chim Acta. 412:2015–2021. 2011. View Article : Google Scholar : PubMed/NCBI
12	Rossler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schüler A, Bornfeld N and Schilling H: Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol. 164:391–394. 2004. View Article : Google Scholar : PubMed/NCBI
13	Marback EF, Arias VEA, Paranhos A Jr, Soares FA, Murphree AL and Erwenne CM: Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol. 87:1224–1228. 2003. View Article : Google Scholar : PubMed/NCBI
14	Houston SK, Murray TG, Wolfe SQ and Fernandes CE: Current update on retinoblastoma. Int Ophthalmol Clin. 51:77–91. 2011. View Article : Google Scholar : PubMed/NCBI
15	Slusarz A, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, MacDonald RS, Besch-Williford CL and Lubahn DB: Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 70:3382–3390. 2010. View Article : Google Scholar : PubMed/NCBI
16	Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Gálvez J and Zarzuelo A: In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol. 35:584–592. 2005. View Article : Google Scholar : PubMed/NCBI
17	Murakami A, Ashida H and Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett. 269:315–325. 2008. View Article : Google Scholar : PubMed/NCBI
18	Granado-Serrano AB, Martin MA, Bravo L, Goya L and Ramos S: Quercetin induces apoptosis via caspase activation, regulation of Bcl-2 and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr. 136:2715–2721. 2006.PubMed/NCBI
19	Duraj J, Zazrivcova K, Bodo J, Sulikova M and Sedlak J: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma. 52:273–279. 2004.
20	Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One. 7:e475162012. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Dela Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Merriam GR Jr: Retinoblastoma; analysis of 17 autopsies. Arch Ophthal. 44:71–108. 1950. View Article : Google Scholar : PubMed/NCBI
23	Carbajal UM: Metastasis in retinoblastoma. Am J Ophthalmol. 48:47–69. 1959. View Article : Google Scholar : PubMed/NCBI
24	Taktikos A: Investigation of retinoblastoma with special reference to histology and prognosis. Br J Ophthalmol. 50:225–234. 1966. View Article : Google Scholar : PubMed/NCBI
25	Rubin CM, Robison LL, Cameron JD, Woods WG, Nesbit ME Jr, Krivit W, Kim TH, Letson RD and Ramsay NK: Intraocular retinoblastoma group V: An analysis of prognostic factors. J Clin Oncol. 3:680–685. 1985. View Article : Google Scholar : PubMed/NCBI
26	Kopelman JE, McLean IW and Rosenberg SH: Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology. 94:371–377. 1987. View Article : Google Scholar : PubMed/NCBI
27	Liu Q, Wang Y, Wang H, Liu Y, Liu T and Kunda PE: Tandem therapy for retinoblastoma: Immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol. 139:1357–1372. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ren MX, Deng XH, Ai F, Yuan GY and Song HY: Effect of quercetin on the proliferation of the human ovarian cancer cell line SKOV-3 in vitro. Exp Ther Med. 10:579–583. 2015.PubMed/NCBI
29	Park CH, Chang JY, Hahm ER, Park S, Kim HK and Yang CH: Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun. 328:227–234. 2005. View Article : Google Scholar : PubMed/NCBI
30	Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:58–61. 1989. View Article : Google Scholar : PubMed/NCBI
31	Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell. 64:327–336. 1991. View Article : Google Scholar : PubMed/NCBI
32	Tang N, Shi L, Yu Z, Dong P, Wang C, Huo X, Zhang B, Huang S, Deng S, Liu K, et al: Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway. Oncotarget. 7:3533–3547. 2016. View Article : Google Scholar : PubMed/NCBI
33	Zhang Z, Zhang H, Peng T, Li D and Xu J: Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma. Oncol Lett. 11:610–618. 2016.PubMed/NCBI
34	Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J and Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1309–1312. 1989. View Article : Google Scholar : PubMed/NCBI
35	Tie J and Desai J: Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog. 17:51–67. 2012. View Article : Google Scholar : PubMed/NCBI